-
UNPARALLELED SCALABILITY
10x increase in productivity compared with conventional CDMOs
-
COST SAVINGS
Up to 50% lower price per batch compared with conventional CDMOs
-
QUALITY
75% lower process failure rates compared with conventional CDMOs
-
Smart Factory
South San Francisco, CA - Preclinical & Clinical Services / Technology Development
- 57,000 Sq Ft
-
Smart Factory
South San Francisco, CA - Preclinical & Clinical Services / Technology Development
- 57,000 Sq Ft
-
Smart Factory
Bridgewater, NJ - Preclinical, Clinical & Commercial Services
- 118,000 Sq Ft
-
Smart Factory
Bridgewater, NJ - Preclinical, Clinical & Commercial Services
- 118,000 Sq Ft
-
Smart Factory - Europe
COMING SOON - Preclinical, Clinical & Commercial Services
-
Smart Factory - Europe
COMING SOON - Preclinical, Clinical & Commercial Services
-
Smart Factory - Asia
COMING SOON - Preclinical, Clinical & Commercial Services
-
Smart Factory - Asia
COMING SOON - Preclinical, Clinical & Commercial Services
- Existing Smart Factories
- Planned Smart Factories
- Manufacturing Services
-
- Advanced Technology
Technology
Powered by Advanced Cell Therapy Manufacturing Technologies
Technology
Powered by Advanced Cell Therapy Manufacturing Technologies
Consumable Cartridge
True end-to-end automation in a closed and automated single-use cartridge
Technology
Powered by Advanced Cell Therapy Manufacturing Technologies
-
Scalability
10x increase in productivity
-
Cost Savings
Up to 50% reduction in cost per batch
-
QUALITY
Reduction in process failure rates
-
FLEXIBILITY
Majority of cell therapy modalities supported
Careers
Do What’s Never Been Done Before
Cellares is always looking for passionate and world-class professionals to join our interdisciplinary team
-
April 14, 2026
First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares’ Automated Cell Shuttle™ Platform
-
April 10, 2025
Cellares and University of Wisconsin School of Medicine and Public Health to Automate Clinical-Scale Production of CRISPR-Edited CAR-T for Solid Tumors
-
February 03, 2026
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies
